Express Press Release Distribution

Accounting
Advertising
Aerospace
Agriculture
Apparel & Fashion
Automotive
Biotech
Chemicals
Computers
Construction
Consumer Services
Defense
Education
Electronics
Energy
Entertainment
Environment
Financial
Food & Beverage
Government
Healthcare
Human Resources
Industrial
International Trade
Internet & Online
Law
Management
Marketing
Media
Non Profit
Pharmaceuticals
Real Estate
Retail
Semiconductors
Small Business
Software
Sports
Telecommunications
Transportation / Logistics
Travel

EPR Archived News

Archived News 2012
~ April
~ March
~ February
~ January

Archived News 2011
~ December
~ November
~ October
~ September
~ August
~ July
~ June
~ May
~ April
~ March
~ February
~ January

Archived News 2010
Archived News 2009
Archived News 2008
Archived News 2007
Archived News 2006
Archived News 2005
Archived News 2004

 

CTL Announces Validation of Reference Samples for use in Regulated Human, Pig, and Mouse ELISPOT Assays

Released on = March 22, 2007, 9:53 pm

Press Release Author = Cellular Technology Limited

Industry = Biotech

Press Release Summary = Cellular Technology Ltd. has validated reference samples for
use in human, pig, and mouse ELISPOT assay systems, which provides a sensitive tool
for monitoring immune response.

Press Release Body = While long employed in the academic research setting, the
ability to obtain valid ELISPOT data on study samples is beginning to greatly
enhance ex vivo immune monitoring capabilities for the biotechnology and
pharmaceutical industries. To be used in a regulated environment, however, the
assay must be validated.

Based on years of research and development, Cellular Technology Ltd. has validated
reference samples for use in human, pig, and mouse ELISPOT assay systems, which
provides a sensitive tool for monitoring immune response. Validation has been
accomplished through assay optimization by defining and documenting technical,
biological, and reagent variables which can influence the ELISPOT assay.
Furthermore, Cellular Technology Ltd. has achieved assay validation through
accomplishing two phases. Phase I included the Qualification Experiments, which
established the precise parameters and acceptance criteria for the validation
experiment. Phase II then included the Validation Experiment and aimed to qualify
one or more reference samples for use in a regulated study. By including both of
these phases, the validation covered, but is not limited to, the following aspects
of the assay structure including assay development, validation plan, validation test
data, and validation report.

The ELISPOT systems capability to use frozen cells makes it possible to qualify
reference samples, which can be used as a comparison in the pre-clinical and
clinical studies. Cellular Technology Ltd. has developed test procedures to evaluate
all key validation parameters, including, but not limited to, accuracy, precision,
limits of detection, limits of quantitation, etc. Because it is sometimes difficult
to find reference materials, specifically for human ELISPOT validation, CTL has
developed a line of characterized and uncharacterized PBMCs for use a reference
samples in human immune monitoring.

For further information on CTL's immune monitoring contract research service or
reference samples, contact info@immunospot.com or call CTL at (216) 791-5084.


Web Site = http://www.immunospot.com

Contact Details = 10515 Carnegie Avenue
Cleveland, Ohio 44106

Telephone: (216) 791-5084
Fax: (216) 791-8814
E-mail: info@immunospot.com

  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...
  •